Results 41 to 50 of about 25,475 (182)

Combined test versus logrank/Cox test in 50 randomised trials

Trials, 2019
Background The logrank test and the Cox proportional hazards model are routinely applied in the design and analysis of randomised controlled trials (RCTs) with time-to-event outcomes.
Patrick Royston, Babak Choodari-Oskooei, Mahesh K. B. Parmar, Jennifer K. Rogers   +3 more
doaj   +1 more source

Using observational study data as an external control group for a clinical trial: an empirical comparison of methods to account for longitudinal missing data

BMC Medical Research Methodology, 2022
Background Observational data are increasingly being used to conduct external comparisons to clinical trials. In this study, we empirically examined whether different methodological approaches to longitudinal missing data affected study conclusions in ...
Vibeke Norvang, Espen A. Haavardsholm, Sara K. Tedeschi, Houchen Lyu, Joseph Sexton, Maria D. Mjaavatten, Tore K. Kvien, Daniel H. Solomon, Kazuki Yoshida   +8 more
doaj   +1 more source

Impact of deintensifying hypoglycaemic drugs in older adults with type 2 diabetes: protocol for an emulation of a target trial

BMJ Open, 2023
Introduction In older adults with type 2 diabetes (T2D), overtreatment with hypoglycaemic drugs (HDs: sulfonylureas, glinides and/or insulins) is frequent and associated with increased 1-year mortality.
Séverine Henrard, Florence Tubach, Lorene Zerah, Dominique Bonnet-Zamponi, Wade Thompson, Antoine Christiaens, Noémie Simon-Tillaux, Alan J. Sinclair, Benoit B. Boland, Yannis Slaouti-Jégou, Béranger Lekens   +10 more
doaj   +1 more source

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source

Informative Censoring in CDK4/6 Inhibitor Adjuvant Therapy for Early Breast Cancer: A Sensitivity Analysis of Invasive Disease-Free Survival in the monarchE Trial

Epidemiology, Biostatistics and Public Health
INTRODUCTION The estimation of survival curves and hazard functions relies on the assumption of non-informative censoring—that is, the censoring time for an individual provides no further information about that person’s likelihood of survival at a ...
Federico Merlo , Fabio Conforti , Vincenzo Bagnardi   +2 more
doaj   +1 more source

Detection of circulating tumor DNA in colorectal cancer patients using a methylation‐specific droplet digital PCR multiplex

Molecular Oncology, EarlyView.
We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto, Louise Raunkilde, Jan Lindebjerg, Mads Malik Aagaard, Christina Therkildsen, Jakob Kleif, Lars Henrik Jensen, Torben Frøstrup Hansen, Rikke Fredslund Andersen   +8 more
wiley   +1 more source

Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials

npj Parkinson's Disease
The use of symptomatic medications represents a challenge for clinical trials of novel medicines designed to slow Parkinson’s disease progression. A time-to-event (TTE) approach using a defined motor progression milestone may mitigate the confounding ...
Gennaro Pagano, Dylan Trundell, Tanya Simuni, Nicola Pavese, Kenneth Marek, Ronald B. Postuma, Nima Shariati, Annabelle Monnet, Emma Moore, Evan W. Davies, Hanno Svoboda, Nathalie Pross, Azad Bonni, Tania Nikolcheva, for the PASADENA Investigators, Prasinezumab Study Group   +15 more
doaj   +1 more source

Lasso regularization for left-censored Gaussian outcome and high-dimensional predictors

BMC Medical Research Methodology, 2018
Background Biological assays for the quantification of markers may suffer from a lack of sensitivity and thus from an analytical detection limit. This is the case of human immunodeficiency virus (HIV) viral load.
Perrine Soret, Marta Avalos, Linda Wittkop, Daniel Commenges, Rodolphe Thiébaut   +4 more
doaj   +1 more source

Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces

MDM Policy & Practice, 2021
Background. Real-world evidence can be a valuable tool when clinical trial data are incomplete or uncertain. Bevacizumab was adopted as first-line therapy for metastatic colorectal cancer (mCRC) based on significant survival improvements in initial ...
Reka E. Pataky, Jaclyn Beca, David Tran, Wei Fang Dai, Erind Dvorani, Wanrudee Isaranuwatchai, Stuart Peacock, Riaz Alvi, Winson Y. Cheung, Craig C. Earle, Scott Gavura, Kelvin K. W. Chan   +11 more
doaj   +1 more source

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

Molecular Oncology, EarlyView.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra, Lucca Paolo Hsu Helmich, Daniel Rodrigues de Bastos, Laura Sichero, Patrícia Savio de Araujo‐Souza, Fabio Passetti, Luisa Lina Villa   +6 more
wiley   +1 more source